{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:45:58Z","timestamp":1794642358919,"version":"4.9.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000320","name":"Alzheimer's Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is an escalating global challenge, with more than 40\u00a0million people affected, and this number is projected to increase to more than 100\u00a0million by 2050. While amyloid-targeting antibody treatments (lecanemab and donanemab) are a significant step forward, the benefits of these therapies remain limited. This highlights the necessity for safe and effective compounds that offer greater therapeutic benefits to the majority of individuals with or at risk of AD. Drug repurposing allows for a cost-effective, time-efficient strategy to accelerate the availability of treatments, owing to the availability of safety information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This study focuses on the third iteration of the Delphi consensus programme aimed at identifying new high-priority drug candidates for repurposing in AD. An international expert panel comprising academics, clinicians and industry representatives was convened. Through a combination of anonymized drug nominations, systemic evidence reviews, iterative consensus rankings, and lay advisory inputs, drug candidates were evaluated and ranked based on rational, non-clinical, and clinical evidence and overall safety profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 80 candidates that were nominated by the expert panel, seven underwent review, with only three candidates meeting the following consensus criteria of relevant mechanisms for targeting neurodegenerative pathways, non-clinical efficacy, and tolerability in older individuals. The three agents were: [1] the live attenuated herpes zoster (HZ) vaccine (Zostavax) [2], sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, and [3] riluzole, a glutamate antagonist. The HZ vaccine additionally offers potential for population-level dementia risk reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This Delphi consensus identified three high-priority drug repurposing candidates for AD with favourable safety profiles and mechanistic plausibility, which are considered suitable for pragmatic clinical trials, including remote or hybrid designs. The PROTECT platform, which supports international cohorts in the UK, Norway, and Canada, offers a well-established means to conduct such trials effectively, thus helping to accelerate the evaluation and potential deployment of these drug candidates to benefit individuals with or at risk for AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01895-4","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:04:20Z","timestamp":1763424260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug repurposing for Alzheimer\u2019s disease: a Delphi consensus and stakeholder consultation"],"prefix":"10.1186","volume":"17","author":[{"given":"Anne","family":"Corbett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Stych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahinoor","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Soto-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Killick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell K. P.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Routledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1895_CR1","unstructured":"International AsD. World Alzheimer Report: Alzheimer\u2019s Disease International. 2016 [Available from: https:\/\/www.alz.co.uk\/research\/world-report-2016"},{"issue":"1","key":"1895_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"1895_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"7","key":"1895_CR4","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1007\/s11033-021-06512-9","volume":"48","author":"T Athar","year":"2021","unstructured":"Athar T, Al Balushi K, Khan SA. Recent advances on drug development and emerging therapeutic agents for Alzheimer\u2019s disease. Mol Biol Rep. 2021;48(7):5629\u201345.","journal-title":"Mol Biol Rep"},{"issue":"8","key":"1895_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"J Langedijk","year":"2015","unstructured":"Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027\u201334.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1895_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56690-4","volume":"16","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou Y, Van Stone A, Cammann D, Tonegawa-Kuji R, Fonseca J, et al. Drug repurposing for Alzheimer\u2019s disease and other neurodegenerative disorders. Nat Commun. 2025;16(1):1755.","journal-title":"Nat Commun"},{"issue":"6168","key":"1895_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.1249543","volume":"343","author":"AK Stewart","year":"2014","unstructured":"Stewart AK. Medicine. How thalidomide works against cancer. Science. 2014;343(6168):256\u20137.","journal-title":"Science"},{"issue":"14","key":"1895_CR8","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096\u20139.","journal-title":"Neurology"},{"issue":"11","key":"1895_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd3869","volume":"11","author":"A Corbett","year":"2012","unstructured":"Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, et al. Drug repositioning for Alzheimer\u2019s disease. Nat Rev Drug Discov. 2012;11(11):833\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1895_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","volume":"16","author":"CAD Ballard","year":"2020","unstructured":"Ballard CAD, Cummings J, O\u2019Brien J, Mills R, Molinuevo JL, Fladby T, et al. Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol. 2020;16(12):661\u201373.","journal-title":"Nat Rev Neurol"},{"key":"1895_CR11","unstructured":"Edison P. GLP-1 drug liraglutide may protect against dementia. Amsterdam: Alzheimer\u2019s Association International Conference; 2024. https:\/\/aaic.alz.org\/releases-2024\/glp-drug-liraglutide-may-protect-against-dementia.asp."},{"issue":"1","key":"1895_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-04011-6","volume":"5","author":"PAM Baloni","year":"2022","unstructured":"Baloni PAM, Buitrago L, Nho K, Moreno H, Huynh K, Brauner B, et al. Multi-omic analyses characterize the ceramide\/sphingomyelin pathway as a therapeutic target in Alzheimer\u2019s disease. Commun Biol. 2022;5(1):1074.","journal-title":"Commun Biol"},{"key":"1895_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bbr.2014.03.046","volume":"268","author":"K Fukumoto","year":"2014","unstructured":"Fukumoto K, Mizoguchi H, Takeuchi H, Horiuchi H, Kawanokuchi J, Jin S, et al. Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid \u03b2-induced memory impairment. Behav Brain Res. 2014;268:88\u201393.","journal-title":"Behav Brain Res"},{"issue":"5","key":"1895_CR14","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/jnr.23799","volume":"95","author":"DFA Becker-Krail","year":"2017","unstructured":"Becker-Krail DFA, Boger HA, Lavin A. Effects of Fingolimod administration in a genetic model of cognitive deficits. J Neurosci Res. 2017;95(5):1174\u201381.","journal-title":"J Neurosci Res"},{"key":"1895_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep41734","volume":"7","author":"P Joshi","year":"2017","unstructured":"Joshi P, Gabrielli M, Ponzoni L, Pelucchi S, Stravalaci M, Beeg M, et al. Fingolimod limits acute A\u03b2 neurotoxicity and promotes synaptic versus extrasynaptic NMDA receptor functionality in hippocampal neurons. Sci Rep. 2017;7:41734.","journal-title":"Sci Rep"},{"issue":"1","key":"1895_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12324","volume":"8","author":"JM Krivinko","year":"2022","unstructured":"Krivinko JM, Erickson SL, MacDonald ML, Garver ME, Sweet RA. Fingolimod mitigates synaptic deficits and psychosis-like behavior in APP\/PSEN1 mice. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2022;8(1):e12324.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"3","key":"1895_CR17","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s12035-021-02613-5","volume":"59","author":"SG Fagan","year":"2022","unstructured":"Fagan SG, Bechet S, Dev KK. Fingolimod rescues memory and improves pathological hallmarks in the 3xTg-AD model of Alzheimer\u2019s disease. Mol Neurobiol. 2022;59(3):1882\u201395.","journal-title":"Mol Neurobiol"},{"issue":"42","key":"1895_CR18","doi-asserted-by":"publisher","first-page":"6954","DOI":"10.1523\/JNEUROSCI.0515-23.2023","volume":"43","author":"P Yin","year":"2023","unstructured":"Yin P, Cai Y, Cui T, Berg AJ, Wang T, Morency DT, et al. Glial sphingosine-mediated epigenetic regulation stabilizes synaptic function in drosophila models of alzheimer\u2019s disease. J Neurosci. 2023;43(42):6954\u201371.","journal-title":"J Neurosci"},{"issue":"1","key":"1895_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12035-018-1040-x","volume":"56","author":"H J\u0119\u015bko","year":"2019","unstructured":"J\u0119\u015bko H, Wencel PL, Lukiw WJ, Strosznajder RP. Modulatory effects of Fingolimod (FTY720) on the expression of sphingolipid metabolism-related genes in an animal model of Alzheimer\u2019s disease. Mol Neurobiol. 2019;56(1):174\u201385.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1895_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47287-1","volume":"9","author":"I Carreras","year":"2019","unstructured":"Carreras I, Aytan N, Choi JK, Tognoni CM, Kowall NW, Jenkins BG, et al. Dual dose-dependent effects of Fingolimod in a mouse model of Alzheimer\u2019s disease. Sci Rep. 2019;9(1):10972.","journal-title":"Sci Rep"},{"key":"1895_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep24939","volume":"6","author":"NCJ Aytan","year":"2016","unstructured":"Aytan NCJ, Carreras I, Brinkmann V, Kowall NW, Jenkins BG, Dedeoglu A. Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer\u2019s disease. Sci Rep. 2016;6:24939.","journal-title":"Sci Rep"},{"issue":"5","key":"1895_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064050","volume":"8","author":"N Takasugi","year":"2013","unstructured":"Takasugi N, Sasaki T, Ebinuma I, Osawa S, Isshiki H, Takeo K, et al. FTY720\/fingolimod, a sphingosine analogue, reduces amyloid-\u03b2 production in neurons. PLoS ONE. 2013;8(5):e64050.","journal-title":"PLoS ONE"},{"key":"1895_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2022.148171","volume":"1799","author":"Y Jung","year":"2023","unstructured":"Jung Y, Lopez-Benitez J, Tognoni CM, Carreras I, Dedeoglu A. Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer\u2019s disease. Brain Res. 2023;1799:148171.","journal-title":"Brain Res"},{"issue":"4","key":"1895_CR24","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00213-020-05452-9","volume":"237","author":"LX Jiang","year":"2020","unstructured":"Jiang LX, Huang GD, Su F, Wang H, Zhang C, Yu X. Vortioxetine administration attenuates cognitive and synaptic deficits in 5\u00d7FAD mice. Psychopharmacology. 2020;237(4):1233\u201343.","journal-title":"Psychopharmacology"},{"key":"1895_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.809541","volume":"12","author":"G Caruso","year":"2021","unstructured":"Caruso G, Grasso M, Fidilio A, Torrisi SA, Musso N, Geraci F, et al. Antioxidant activity of Fluoxetine and Vortioxetine in a non-transgenic animal model of Alzheimer\u2019s disease. Front Pharmacol. 2021;12:809541.","journal-title":"Front Pharmacol"},{"key":"1895_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00693","volume":"10","author":"SA Torrisi","year":"2019","unstructured":"Torrisi SA, Geraci F, Tropea MR, Grasso M, Caruso G, Fidilio A, et al. Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by A\u03b2(1\u201342) oligomers in mice: a key role of transforming growth factor-\u03b21. Front Pharmacol. 2019;10:693.","journal-title":"Front Pharmacol"},{"key":"1895_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pbb.2015.05.013","volume":"135","author":"Y Li","year":"2015","unstructured":"Li Y, Abdourahman A, Tamm JA, Pehrson AL, S\u00e1nchez C, Gulinello M. Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice. Pharmacol Biochem Behav. 2015;135:70\u201382.","journal-title":"Pharmacol Biochem Behav"},{"issue":"13","key":"1895_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/WNR.0000000000001499","volume":"31","author":"M Liu","year":"2020","unstructured":"Liu M, Qian T, Zhou W, Tao X, Sang S, Zhao L. Beneficial effects of low-dose lithium on cognitive ability and pathological alteration of Alzheimer\u2019s disease transgenic mice model. Neuroreport. 2020;31(13):943\u201351.","journal-title":"Neuroreport"},{"issue":"2","key":"1895_CR29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-220813","volume":"91","author":"RK Fenech","year":"2023","unstructured":"Fenech RK, Hamstra SI, Finch MS, Ryan CR, Marko DM, Roy BD, et al. Low-dose lithium supplementation influences GSK3\u03b2 activity in a brain region specific manner in C57BL6 male mice. J Alzheimers Dis. 2023;91(2):615\u201326.","journal-title":"J Alzheimers Dis"},{"key":"1895_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.aanat.2016.10.002","volume":"209","author":"EL Schaeffer","year":"2017","unstructured":"Schaeffer EL, Catanozi S, West MJ, Gattaz WF. Stereological investigation of the CA1 pyramidal cell layer in untreated and lithium-treated 3xTg-AD and wild-type mice. Ann Anat. 2017;209:51\u201360.","journal-title":"Ann Anat"},{"issue":"13","key":"1895_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2174\/1567205015666180904154446","volume":"15","author":"EN Wilson","year":"2018","unstructured":"Wilson EN, Do Carmo S, Iulita MF, Hall H, Austin GL, Jia DT, et al. Microdose lithium NP03 diminishes pre-plaque oxidative damage and neuroinflammation in a rat model of Alzheimer\u2019s-like amyloidosis. Curr Alzheimer Res. 2018;15(13):1220\u201330.","journal-title":"Curr Alzheimer Res"},{"issue":"7","key":"1895_CR32","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s10571-020-00916-0","volume":"41","author":"M Toricelli","year":"2021","unstructured":"Toricelli M, Evangelista SR, Buck HS, Viel TA. Microdose lithium treatment reduced inflammatory factors and neurodegeneration in organotypic hippocampal culture of old SAMP-8 mice. Cell Mol Neurobiol. 2021;41(7):1509\u201320.","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"1895_CR33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12035-013-8580-x","volume":"49","author":"WB Lai","year":"2014","unstructured":"Lai WB, Wang BJ, Hu MK, Hsu WM, Her GM, Liao YF. Ligand-dependent activation of EphA4 signaling regulates the proteolysis of amyloid precursor protein through a Lyn-mediated pathway. Mol Neurobiol. 2014;49(2):1055\u201368.","journal-title":"Mol Neurobiol"},{"key":"1895_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-117","volume":"9","author":"G Dhawan","year":"2012","unstructured":"Dhawan G, Combs CK. Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer\u2019s disease. J Neuroinflammation. 2012;9:117.","journal-title":"J Neuroinflammation"},{"issue":"10","key":"1895_CR35","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.neurobiolaging.2011.10.027","volume":"33","author":"G Dhawan","year":"2012","unstructured":"Dhawan G, Floden AM, Combs CK. Amyloid-\u03b2 oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol Aging. 2012;33(10):2247\u201361.","journal-title":"Neurobiol Aging"},{"key":"1895_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26123736","author":"SS Ghanem","year":"2021","unstructured":"Ghanem SS, Fayed HS, Zhu Q, Lu JH, Vaikath NN, Ponraj J, et al. Natural alkaloid compounds as inhibitors for Alpha-Synuclein seeded fibril formation and toxicity. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26123736.","journal-title":"Molecules"},{"issue":"3\u20134","key":"1895_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuint.2008.12.001","volume":"54","author":"M Mousavi","year":"2009","unstructured":"Mousavi M, Hellstr\u00f6m-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int. 2009;54(3\u20134):237\u201344.","journal-title":"Neurochem Int"},{"issue":"3","key":"1895_CR38","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3233\/JAD-220287","volume":"88","author":"DM Cairns","year":"2022","unstructured":"Cairns DM, Itzhaki RF, Kaplan DL. Potential involvement of varicella zoster virus in Alzheimer\u2019s disease via reactivation of quiescent herpes simplex virus type 1. J Alzheimers Dis. 2022;88(3):1189\u2013200.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1895_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2216625","volume":"19","author":"AS Bukhbinder","year":"2023","unstructured":"Bukhbinder AS, Ling Y, Harris K, Jiang X, Schulz PE. Do vaccinations influence the development of Alzheimer disease? Hum Vaccin Immunother. 2023;19(2):2216625.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"1895_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40264-023-01295-3","volume":"46","author":"CS Benn","year":"2023","unstructured":"Benn CS, Amenyogbe N, Bj\u00f6rkman A, Dom\u00ednguez-Andr\u00e9s J, Fish EN, Flanagan KL, et al. Implications of non-specific effects for testing, approving, and regulating vaccines. Drug Saf. 2023;46(5):439\u201348.","journal-title":"Drug Saf"},{"issue":"2","key":"1895_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3415","volume":"14","author":"S Shah","year":"2024","unstructured":"Shah S, Dahal K, Thapa S, Subedi P, Paudel BS, Chand S, et al. Herpes zoster vaccination and the risk of dementia: a systematic review and meta-analysis. Brain Behav. 2024;14(2):e3415.","journal-title":"Brain Behav"},{"issue":"8062","key":"1895_CR42","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-025-08800-x","volume":"641","author":"M Eyting","year":"2025","unstructured":"Eyting M, Xie M, Michalik F, He\u00df S, Chung S, Geldsetzer P. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025;641(8062):438\u201346.","journal-title":"Nature"},{"issue":"23","key":"1895_CR43","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1001\/jama.2025.5013","volume":"333","author":"M Pomirchy","year":"2025","unstructured":"Pomirchy M, Bommer C, Pradella F, Michalik F, Peters R, Geldsetzer P. Herpes zoster vaccination and dementia occurrence. JAMA. 2025;333(23):2083\u201392.","journal-title":"JAMA"},{"issue":"10","key":"1895_CR44","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1038\/s41591-024-03201-5","volume":"30","author":"M Taquet","year":"2024","unstructured":"Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with lower risk of dementia. Nat Med. 2024;30(10):2777\u201381.","journal-title":"Nat Med"},{"issue":"12","key":"1895_CR45","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s43587-021-00138-z","volume":"1","author":"J Fang","year":"2021","unstructured":"Fang J, Zhang P, Zhou Y, Chiang CW, Tan J, Hou Y, et al. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer\u2019s disease. Nat Aging. 2021;1(12):1175\u201388.","journal-title":"Nat Aging"},{"issue":"3","key":"1895_CR46","doi-asserted-by":"publisher","first-page":"e62511","DOI":"10.1016\/j.neurobiolaging.2011.03.018","volume":"33","author":"L Orejana","year":"2012","unstructured":"Orejana L, Barros-Minones L, Jordan J, Puerta E, Aguirre N. Sildenafil ameliorates cognitive deficits and Tau pathology in a senescence-accelerated mouse model. Neurobiol Aging. 2012;33(3):e62511\u201320.","journal-title":"Neurobiol Aging"},{"issue":"8","key":"1895_CR47","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/j.1476-5381.2011.01517.x","volume":"164","author":"M Cuadrado-Tejedor","year":"2011","unstructured":"Cuadrado-Tejedor M, Hervias I, Ricobaraza A, Puerta E, Perez-Roldan JM, Garcia-Barroso C, et al. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of alzheimer\u2019s disease. Br J Pharmacol. 2011;164(8):2029\u201341.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1895_CR48","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3233\/JAD-161006","volume":"60","author":"M Sheng","year":"2017","unstructured":"Sheng M, Lu H, Liu P, Li Y, Ravi H, Peng S-L, et al. Sildenafil improves vascular and metabolic function in patients with Alzheimer\u2019s disease. J Alzheimers Dis. 2017;60(4):1351\u201364.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1895_CR49","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/gerona\/glu106","volume":"70","author":"L Orejana","year":"2015","unstructured":"Orejana L, Barros-Minones L, Jordan J, Cedazo-Minguez A, Tordera RM, Aguirre N, et al. Sildenafil decreases BACE1 and cathepsin B levels and reduces APP amyloidogenic processing in the SAMP8 mouse. The journals of gerontologyseries A, biological sciences and medical sciences. 2015;70(6):675\u201385.","journal-title":"The journals of gerontologyseries A, biological sciences and medical sciences"},{"issue":"4","key":"1895_CR50","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0960327120960775","volume":"40","author":"MA Ibrahim","year":"2021","unstructured":"Ibrahim MA, Haleem M, AbdelWahab SA, Abdel-Aziz AM. Sildenafil ameliorates Alzheimer disease via the modulation of vascular endothelial growth factor and vascular cell adhesion molecule-1 in rats. Hum Exp Toxicol. 2021;40(4):596\u2013607.","journal-title":"Hum Exp Toxicol"},{"key":"1895_CR51","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbr.2013.05.017","volume":"250","author":"J Zhang","year":"2013","unstructured":"Zhang J, Guo J, Zhao X, Chen Z, Wang G, Liu A, et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP\/PS1 transgenic mice. Behav Brain Res. 2013;250:230\u20137.","journal-title":"Behav Brain Res"},{"issue":"6","key":"1895_CR52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.exger.2013.03.001","volume":"48","author":"L Orejana","year":"2013","unstructured":"Orejana L, Barros-Minones L, Aguirre N, Puerta E. Implication of JNK pathway on Tau pathology and cognitive decline in a senescence-accelerated mouse model. Exp Gerontol. 2013;48(6):565\u201371.","journal-title":"Exp Gerontol"},{"issue":"3","key":"1895_CR53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3340\/jkns.2016.59.3.259","volume":"59","author":"SK Sung","year":"2016","unstructured":"Sung SK, Woo JS, Kim YH, Son DW, Lee SW, Song GS. Sildenafil ameliorates advanced glycation end products-induced mitochondrial dysfunction in HT-22 hippocampal neuronal cells. J Korean Neurosurg Soc. 2016;59(3):259\u201368.","journal-title":"J Korean Neurosurg Soc"},{"issue":"13","key":"1895_CR54","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.3390\/ijms21134667","volume":"21","author":"K Golshiri","year":"2020","unstructured":"Golshiri K, Ataei Ataabadi E, Brandt R, van der Pluijm I, de Vries R, Danser J, et al. Chronic sildenafil treatment improves vasomotor function in a mouse model of accelerated aging. Int J Mol Sci. 2020;21(13):4667. https:\/\/doi.org\/10.3390\/ijms21134667.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1895_CR55","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.neurobiolaging.2013.09.002","volume":"35","author":"D Puzzo","year":"2014","unstructured":"Puzzo D, Loreto C, Giunta S, Musumeci G, Frasca G, Podda MV, et al. Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiol Aging. 2014;35(3):520\u201331.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1895_CR56","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3233\/JAD-190128","volume":"70","author":"N Samudra","year":"2019","unstructured":"Samudra N, Motes M, Lu H, Sheng M, Diaz-Arrastia R, Devous M, et al. A pilot study of changes in medial temporal lobe fractional amplitude of low frequency fluctuations after sildenafil administration in patients with Alzheimer\u2019s disease. J Alzheimers Dis. 2019;70(1):163\u201370.","journal-title":"J Alzheimers Dis"},{"key":"1895_CR57","doi-asserted-by":"publisher","unstructured":"Ketabforoush AHME, Chegini R, Barati S, Tahmasebi F, Moghisseh B, Joghataei MT, et al. Masitinib: the promising actor in the next season of the amyotrophic lateral sclerosis treatment series. Apr:160. Biomedicine & pharmacotherapy.\u20092023. p. 114378. https:\/\/doi.org\/10.1016\/j.biopha.2023.114378.","DOI":"10.1016\/j.biopha.2023.114378"},{"key":"1895_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neulet.2014.07.050","volume":"580","author":"S-c Ren","year":"2014","unstructured":"Ren S-c, Chen P-z, Jiang H-h, Mi Z, Xu F, Hu B, et al. Persistent sodium currents contribute to Abeta1-42-induced hyperexcitation of hippocampal CA1 pyramidal neurons. Neurosci Lett. 2014;580:62\u20137.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1895_CR59","first-page":"36","volume":"22","author":"S-C Ren","year":"2015","unstructured":"Ren S-C, Shao H, Ji W-G, Jiang H-H, Xu F, Chen P-Z, et al. Riluzole prevents soluble Abeta1-42 oligomers-induced perturbation of spontaneous discharge in the hippocampal CA1 region of rats. Amyloid: Int J Experimental Clin Invest : Official J Int Soc Amyloidosis. 2015;22(1):36\u201344.","journal-title":"Amyloid: Int J Experimental Clin Invest : Official J Int Soc Amyloidosis"},{"issue":"3","key":"1895_CR60","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13311-022-01339-z","volume":"20","author":"MT Usmani","year":"2023","unstructured":"Usmani MT, Krattli RP Jr., El-Khatib SM, Le ACD, Smith SM, Baulch JE, et al. Bdnf augmentation using riluzole reverses doxorubicin-induced decline in cognitive function and neurogenesis. Neurotherapeutics. 2023;20(3):838\u201352.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"1895_CR61","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/mp.2016.33","volume":"22","author":"AC Pereira","year":"2017","unstructured":"Pereira AC, Gray JD, Kogan JF, Davidson RL, Rubin TG, Okamoto M, et al. Age and Alzheimer\u2019s disease gene expression profiles reversed by the glutamate modulator riluzole. Mol Psychiatry. 2017;22(2):296\u2013305.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"1895_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/membranes12030317","volume":"12","author":"X-Y Wang","year":"2022","unstructured":"Wang X-Y, Liu W-G, Hou A-S, Song Y-X, Ma Y-L, Wu X-D, et al. Dysfunction of EAAT3 aggravates LPS-induced post-operative cognitive dysfunction. Membranes. 2022;12(3):317. https:\/\/doi.org\/10.3390\/membranes12030317.","journal-title":"Membranes"},{"key":"1895_CR63","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2022.04.051","volume":"610","author":"K Saba","year":"2022","unstructured":"Saba K, Patel AB. Riluzole restores memory and brain energy metabolism in AbetaPP-PS1 mouse model of alzheimer\u2019s disease. Biochem Biophys Res Commun. 2022;610:140\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1895_CR64","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jnc.13230","volume":"135","author":"HC Hunsberger","year":"2015","unstructured":"Hunsberger HC, Weitzner DS, Rudy CC, Hickman JE, Libell EM, Speer RR, et al. Riluzole rescues glutamate alterations, cognitive deficits, and Tau pathology associated with P301L Tau expression. J Neurochem. 2015;135(2):381\u201394.","journal-title":"J Neurochem"},{"issue":"1","key":"1895_CR65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41398-018-0201-z","volume":"8","author":"M Okamoto","year":"2018","unstructured":"Okamoto M, Gray JD, Larson CS, Kazim SF, Soya H, McEwen BS, et al. Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a Transgenic mouse model of early-onset alzheimer\u2019s disease. Translational Psychiatry. 2018;8(1):153\u2013z.","journal-title":"Translational Psychiatry"},{"key":"1895_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.biopha.2016.12.067","volume":"87","author":"Z Mokhtari","year":"2017","unstructured":"Mokhtari Z, Baluchnejadmojarad T, Nikbakht F, Mansouri M, Roghani M. Riluzole ameliorates learning and memory deficits in Abeta25-35-induced rat model of alzheimer\u2019s disease and is independent of cholinoceptor activation. Biomed pharmacotherapy = Biomedecine Pharmacotherapie. 2017;87:135\u201344.","journal-title":"Biomed pharmacotherapy = Biomedecine Pharmacotherapie"},{"issue":"52","key":"1895_CR67","doi-asserted-by":"publisher","first-page":"18733","DOI":"10.1073\/pnas.1421285111","volume":"111","author":"AC Pereira","year":"2014","unstructured":"Pereira AC, Lambert HK, Grossman YS, Dumitriu D, Waldman R, Jannetty SK, et al. Glutamatergic regulation prevents hippocampal-dependent age-related cognitive decline through dendritic spine clustering. Proc Natl Acad Sci USA. 2014;111(52):18733\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"1895_CR68","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1093\/brain\/awab222","volume":"144","author":"DC Matthews","year":"2021","unstructured":"Matthews DC, Mao X, Dowd K, Tsakanikas D, Jiang CS, Meuser C, et al. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer\u2019s disease. Brain. 2021;144(12):3742\u201355.","journal-title":"Brain"},{"issue":"2","key":"1895_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020331","volume":"13","author":"PBM Bascu\u00f1ana","year":"2023","unstructured":"Bascu\u00f1ana PBM, M\u00f6hle L, Wu J, Br\u00fcning T, Eiriz I, Jansone B, et al. Time- and sex-dependent effects of Fingolimod treatment in a mouse model of Alzheimer\u2019s disease. Biomolecules. 2023;13(2):331.","journal-title":"Biomolecules"},{"key":"1895_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031378","author":"M Garad","year":"2021","unstructured":"Garad M, Edelmann E, Le\u00dfmann V. Impairment of spike-timing-dependent plasticity at Schaffer collateral-CA1 synapses in adult APP\/PS1 mice depends on proximity of A\u03b2 plaques. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22031378.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1895_CR71","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1124\/jpet.116.233924","volume":"358","author":"AL Pehrson","year":"2016","unstructured":"Pehrson AL, Hillhouse TM, Haddjeri N, Rovera R, Porter JH, M\u00f8rk A, et al. Task- and treatment length-dependent effects of Vortioxetine on Scopolamine-induced cognitive dysfunction and hippocampal extracellular acetylcholine in rats. J Pharmacol Exp Ther. 2016;358(3):472\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1895_CR72","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/ijnp\/pyx004","volume":"20","author":"Y Li","year":"2017","unstructured":"Li Y, Sanchez C, Gulinello M. Distinct antidepressant-like and cognitive effects of antidepressants with different mechanisms of action in middle-aged female mice. Int J Neuropsychopharmacol. 2017;20(6):510\u20135.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1895_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.603979","volume":"11","author":"SBC Alboni","year":"2021","unstructured":"Alboni SBC, Colliva C, Radighieri G, Blom JMC, Brunello N, Tascedda F. Vortioxetine prevents lipopolysaccharide-induced memory impairment without inhibiting the initial inflammatory cascade. Front Pharmacol. 2021;11:603979.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1895_CR74","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1176\/appi.ajp.2019.19050561","volume":"177","author":"EJ Lenze","year":"2020","unstructured":"Lenze EJ, Stevens A, Waring JD, Pham VT, Haddad R, Shimony J, et al. Augmenting computerized cognitive training with vortioxetine for age-related cognitive decline: a randomized controlled trial. Am J Psychiatry. 2020;177(6):548\u201355.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1895_CR75","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jagp.2023.01.004","volume":"31","author":"JD Waring","year":"2023","unstructured":"Waring JD, Williams SE, Stevens A, Pogar\u010di\u0107 A, Shimony JS, Snyder AZ, et al. Combined cognitive training and vortioxetine mitigates age-related declines in functional brain network integrity. Am J Geriatr Psychiatry. 2023;31(6):385\u201397.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"1895_CR76","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/YIC.0000000000000376","volume":"36","author":"SN Tan","year":"2021","unstructured":"Tan SN, Tan C. Vortioxetine improves cognition in mild cognitive impairment. Int Clin Psychopharmacol. 2021;36(6):279\u201387.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"1895_CR77","first-page":"104","volume":"10","author":"MA Nunes","year":"2013","unstructured":"Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer\u2019s disease. Curr Alzheimer Res. 2013;10(1):104\u20137.","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"1895_CR78","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1192\/bjp.2019.76","volume":"215","author":"OV Forlenza","year":"2019","unstructured":"Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry. 2019;215(5):668\u201374.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"1895_CR79","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/gps.1964","volume":"23","author":"A Macdonald","year":"2008","unstructured":"Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2008;23(7):704\u201311.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1895_CR80","doi-asserted-by":"publisher","unstructured":"Gonzales MM, Garbarino VR, Kautz TF, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nat Med. 2023;29(10):2481\u20132488. https:\/\/doi.org\/10.1038\/s41591-023-02543-w.","DOI":"10.1038\/s41591-023-02543-w"},{"issue":"1","key":"1895_CR81","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/cr400307e","volume":"114","author":"J RJLMBJB","year":"2014","unstructured":"J RJLMBJB. (-)-Cytisine and derivatives: synthesis, reactivity, and applications. Chem Rev. 2014;114(1):712\u201378.","journal-title":"Chem Rev"},{"issue":"3","key":"1895_CR82","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/JAD-2012-121447","volume":"33","author":"R Ni","year":"2013","unstructured":"Ni R, Marutle A, Nordberg A. Modulation of \u03b17 nicotinic acetylcholine receptor and fibrillar amyloid-\u03b2 interactions in alzheimer\u2019s disease brain. J Alzheimers Dis. 2013;33(3):841\u201351.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1895_CR83","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.nbd.2003.11.024","volume":"15","author":"E Hellstr\u00f6m-Lindahl","year":"2004","unstructured":"Hellstr\u00f6m-Lindahl E, Mousavi M, Ravid R, Nordberg A. Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer\u2019s patients. Neurobiol Dis. 2004;15(2):351\u201360.","journal-title":"Neurobiol Dis"},{"issue":"22","key":"1895_CR84","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384.","journal-title":"N Engl J Med"},{"issue":"10","key":"1895_CR85","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/cis638","volume":"55","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. Persistence of the efficacy of Zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320\u20138.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1895_CR86","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1365-2796.2011.02359.x","volume":"269","author":"D Gilden","year":"2011","unstructured":"Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269(5):496\u2013506.","journal-title":"J Intern Med"},{"key":"1895_CR87","first-page":"11","volume":"2019","author":"AM Gagliardi","year":"2019","unstructured":"Gagliardi AM, Andriolo BN, Torloni MR, Soares BG, de Oliveira Gomes J, Andriolo RB, et al. Vaccines for preventing herpes Zoster in older adults. Cochrane Database Syst Rev. 2019;2019:11.","journal-title":"Cochrane Database Syst Rev"},{"key":"1895_CR88","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.coi.2019.02.005","volume":"59","author":"NL Sullivan","year":"2019","unstructured":"Sullivan NL, Eberhardt CS, Wieland A, Vora KA, Pulendran B, Ahmed R. Understanding the immunology of the Zostavax shingles vaccine. Curr Opin Immunol. 2019;59:25\u201330.","journal-title":"Curr Opin Immunol"},{"key":"1895_CR89","first-page":"341","volume":"342","author":"A Weinberg","year":"2010","unstructured":"Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341\u201357.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"10","key":"1895_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045871","volume":"11","author":"A Lophatananon","year":"2021","unstructured":"Lophatananon A, Mekli K, Cant R, Burns A, Dobson C, Itzhaki R, et al. Shingles, Zostavax vaccination and risk of developing dementia: a nested case-control study-results from the UK biobank cohort. BMJ Open. 2021;11(10):e045871.","journal-title":"BMJ Open"},{"issue":"2","key":"1895_CR91","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3233\/JAD-221231","volume":"95","author":"K Harris","year":"2023","unstructured":"Harris K, Ling Y, Bukhbinder AS, Chen L, Phelps KN, Cruz G, et al. The impact of routine vaccinations on Alzheimer\u2019s disease risk in persons 65 years and older: a claims-based cohort study using propensity score matching. J Alzheimers Dis. 2023;95(2):703\u201318.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"1895_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257405","volume":"16","author":"JF Scherrer","year":"2021","unstructured":"Scherrer JF, Salas J, Wiemken TL, Hoft DF, Jacobs C, Morley JE. Impact of herpes Zoster vaccination on incident dementia: a retrospective study in two patient cohorts. PLoS ONE. 2021;16(11):e0257405.","journal-title":"PLoS ONE"},{"key":"1895_CR93","doi-asserted-by":"publisher","unstructured":"Schneir C, McCarthy A, Morales D, Akbari R, Sofat A, Dale R, Takhar C, Mamas R, Khunti M, Zaccardi K, Sudlow F, Wilkinson C. T.,. Antipsychotic prescribing and mortality in people with dementia before and during the COVID-19 pandemic: retrospective cohort study. Lancet Healthy Longevity. 2023. https:\/\/doi.org\/10.1016\/S2666\/7568.23.00105\/8.","DOI":"10.1016\/S2666\/7568.23.00105\/8"},{"issue":"8","key":"1895_CR94","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrd2030","volume":"5","author":"HA Ghofrani","year":"2006","unstructured":"Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5(8):689\u2013702.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1895_CR95","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.bbrc.2018.04.128","volume":"500","author":"Y Son","year":"2018","unstructured":"Son Y, Kim K, Cho HR. Sildenafil protects neuronal cells from mitochondrial toxicity induced by \u03b2-amyloid peptide via ATP-sensitive K(+) channels. Biochem Biophys Res Commun. 2018;500(2):504\u201310.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1895_CR96","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.pbb.2004.09.019","volume":"79","author":"BD Devan","year":"2004","unstructured":"Devan BD, Sierra-Mercado D Jr., Jimenez M, Bowker JL, Duffy KB, Spangler EL, et al. Phosphodiesterase Inhibition by sildenafil citrate attenuates the learning impairment induced by Blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav. 2004;79(4):691\u20139.","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"1895_CR97","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00213-005-0232-z","volume":"183","author":"BD Devan","year":"2006","unstructured":"Devan BD, Bowker JL, Duffy KB, Bharati IS, Jimenez M, Sierra-Mercado D Jr., et al. Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology. 2006;183(4):439\u201345.","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"1895_CR98","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejphar.2007.02.008","volume":"563","author":"BD Devan","year":"2007","unstructured":"Devan BD, Pistell PJ, Daffin LW Jr., Nelson CM, Duffy KB, Bowker JL, et al. Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine Methyl ester. Eur J Pharmacol. 2007;563(1\u20133):134\u201340.","journal-title":"Eur J Pharmacol"},{"issue":"25","key":"1895_CR99","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","volume":"29","author":"D Puzzo","year":"2009","unstructured":"Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, et al. Phosphodiesterase 5 Inhibition improves synaptic function, memory, and amyloid-beta load in an alzheimer\u2019s disease mouse model. J Neurosci. 2009;29(25):8075\u201386.","journal-title":"J Neurosci"},{"issue":"6","key":"1895_CR100","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1017\/S1461145713001533","volume":"17","author":"F Jin","year":"2014","unstructured":"Jin F, Gong QH, Xu YS, Wang LN, Jin H, Li F, et al. Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP\/PS1 Transgenic mice by stimulation of NO\/cGMP signalling. Int J Neuropsychopharmacol. 2014;17(6):871\u201381.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1895_CR101","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mad.2015.07.002","volume":"150","author":"L Zhu","year":"2015","unstructured":"Zhu L, Yang JY, Xue X, Dong YX, Liu Y, Miao FR, et al. A novel phosphodiesterase-5 inhibitor: yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP\/PS1 transgenic mice model. Mech Ageing Dev. 2015;150:34\u201345.","journal-title":"Mech Ageing Dev"},{"key":"1895_CR102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbr.2012.10.060","volume":"240","author":"A Palmeri","year":"2013","unstructured":"Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. Behav Brain Res. 2013;240:11\u201320.","journal-title":"Behav Brain Res"},{"issue":"1","key":"1895_CR103","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/NRE-131022","volume":"34","author":"BD Devan","year":"2014","unstructured":"Devan BD, Pistell PJ, Duffy KB, Kelley-Bell B, Spangler EL, Ingram DK. Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline. NeuroRehabilitation. 2014;34(1):101\u201311.","journal-title":"NeuroRehabilitation"},{"key":"1895_CR104","first-page":"866","volume":"302","author":"X Huo","year":"2023","unstructured":"Huo X, Finkelstein J. Using big data to uncover association between sildenafil use and reduced risk of alzheimer\u2019s disease. Stud Health Technol Inf. 2023;302:866\u201370.","journal-title":"Stud Health Technol Inf"},{"issue":"5","key":"1895_CR105","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac247","volume":"4","author":"RJ Desai","year":"2022","unstructured":"Desai RJ, Mahesri M, Lee SB, Varma VR, Loeffler T, Schilcher I, et al. No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer\u2019s disease and related dementia: results from the drug repurposing for effective Alzheimer\u2019s medicines study. Brain Commun. 2022;4(5):fcac247.","journal-title":"Brain Commun"},{"issue":"10","key":"1895_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292863","volume":"18","author":"DS Henry","year":"2023","unstructured":"Henry DS, Pellegrino RG. A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer\u2019s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial. PLoS One. 2023;18(10):e0292863.","journal-title":"PLoS One"},{"key":"1895_CR107","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2009.00116.x","author":"MC Bellingham","year":"2011","unstructured":"Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011. https:\/\/doi.org\/10.1111\/j.1755-5949.2009.00116.x.","journal-title":"CNS Neurosci Ther"},{"key":"1895_CR108","first-page":"61","volume":"7","author":"M Hinchcliffe","year":"2017","unstructured":"Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61\u201370.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"1895_CR109","doi-asserted-by":"publisher","unstructured":"Spangler PT, West JC, Dempsey CL, Possemato K, Bartolanzo D, Aliaga P et al. Randomized controlled trial of riluzole augmentation for posttraumatic stress disorder: efficacy of a glutamatergic modulator for Antidepressant-Resistant symptoms. J Clin Psychiatry. 2020;81(6). https:\/\/doi.org\/10.4088\/JCP.20m13233.","DOI":"10.4088\/JCP.20m13233"},{"key":"1895_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884155","volume":"13","author":"O Vasiliu","year":"2022","unstructured":"Vasiliu O. Investigational drugs for the treatment of depression (part 2): glutamatergic, cholinergic, sestrin modulators, and other agents. Front Pharmacol. 2022;13:884155.","journal-title":"Front Pharmacol"},{"issue":"1 Suppl","key":"1895_CR111","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3171\/2012.4.AOSPINE1259","volume":"17","author":"MG Fehlings","year":"2012","unstructured":"Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS, et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN phase I clinical trial. J Neurosurg Spine. 2012;17(1 Suppl):151\u20136.","journal-title":"J Neurosurg Spine"},{"issue":"3","key":"1895_CR112","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1474-4422(21)00457-9","volume":"21","author":"G Coarelli","year":"2022","unstructured":"Coarelli G, Heinzmann A, Ewenczyk C, Fischer C, Chupin M, Monin ML, et al. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2022;21(3):225\u201333.","journal-title":"Lancet Neurol"},{"key":"1895_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010029","author":"H Cho","year":"2020","unstructured":"Cho H, Shukla S. Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis. Pharmaceuticals (Basel). 2020. https:\/\/doi.org\/10.3390\/ph14010029.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"1895_CR114","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/jnc.15224","volume":"156","author":"KN Hascup","year":"2021","unstructured":"Hascup KN, Findley CA, Britz J, Esperant-Hilaire N, Broderick SO, Delfino K, et al. Riluzole attenuates glutamatergic tone and cognitive decline in A\u03b2PP\/PS1 mice. J Neurochem. 2021;156(4):513\u201323.","journal-title":"J Neurochem"},{"issue":"1","key":"1895_CR115","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3233\/JAD-221245","volume":"94","author":"CA Findley","year":"2023","unstructured":"Findley CA, McFadden SA, Cox MF, Sime LN, Peck MR, Quinn K, et al. Prodromal glutamatergic modulation with riluzole impacts glucose homeostasis and spatial cognition in Alzheimer\u2019s disease mice. J Alzheimers Dis. 2023;94(1):371\u201392.","journal-title":"J Alzheimers Dis"},{"key":"1895_CR116","doi-asserted-by":"publisher","first-page":"110077","DOI":"10.1016\/j.pnpbp.2020.110077","volume":"108","author":"Y Yang","year":"2021","unstructured":"Yang Y, Ji W-G, Zhang Y-J, Zhou L-P, Chen H, Yang N, et al. Riluzole ameliorates soluble Abeta(1\u201342)-induced impairments in Spatial memory by modulating the glutamatergic\/GABAergic balance in the dentate gyrus. Prog Neuro-psychopharmacol Biol Psychiatry. 2021;108:110077.","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"key":"1895_CR117","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s11062-019-09820-w","volume":"51","author":"Z Mokhtari","year":"2019","unstructured":"Mokhtari Z, Baluchnejadmojarad T, Nikbakht F, et al. Effect of riluzole, a glutamate release inhibitor, on synaptic plasticity in the intrahippocampal A\u03b2 rat model of alzheimer\u2019s disease. Neurophysiology. 2019;51:266\u201371.","journal-title":"Neurophysiology"},{"key":"1895_CR118","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neuropharm.2019.02.023","volume":"150","author":"SL Lesuis","year":"2019","unstructured":"Lesuis SL, Kaplick PM, Lucassen PJ, Krugers HJ. Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APPswe\/PS1dE9 mice. Neuropharmacology. 2019;150:175\u201383.","journal-title":"Neuropharmacology"},{"issue":"3","key":"1895_CR119","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4103\/0253-7613.96337","volume":"44","author":"P Rinwa","year":"2012","unstructured":"Rinwa P, Jaggi AS, Singh N. Pharmacological investigation of memory restorative effect of riluzole in mice. Indian J Pharmacol. 2012;44(3):366\u201371.","journal-title":"Indian J Pharmacol"},{"issue":"2","key":"1895_CR120","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4103\/jrptps.JRPTPS_69_18","volume":"8","author":"S Andalib","year":"2019","unstructured":"Andalib S, Ziaee M, Mozafari F, Hosseini R, Anoush M. Comparison of donepezil and riluzole in improving spatial memory of male Wistar rats. Journal of Reports in Pharmaceutical Sciences. 2019;8(2):211\u20136.","journal-title":"Journal of Reports in Pharmaceutical Sciences"},{"issue":"3","key":"1895_CR121","volume":"2012","author":"RG Miller","year":"2012","unstructured":"Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012(3):CD001447.","journal-title":"Cochrane Database Syst Rev"},{"key":"1895_CR122","unstructured":"Yankner DA. BA ALNZQCCJLMDDHSLERPYMHSLEB. Lithium deficiency and the onset of alzheimer\u2019s disease. Nature. 2025."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01895-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:04:23Z","timestamp":1763424263000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01895-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01895-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Clive Ballard has received consulting fees from Acadia pharmaceutical company, AARP, Addex pharmaceutical company, Eli Lily, Enterin pharmaceutical company, GWPharm, H.Lundbeck pharmaceutical company,\u202fNovartis pharmaceutical company,\u202fJanssen Pharmaceuticals, Johnson and Johnson pharmaceuticals, Novo Nordisk pharmaceutical company, Orion Corp pharmaceutical company, Otsuka America Pharm Inc, Sunovion Pharm. Inc, Suven pharmaceutical company, Roche pharmaceutical company, Biogen pharmaceutical company, Synexus clinical research organization and tauX pharmaceutical company and research funding from Synexus clinical research organization, Roche pharmaceutical company, Novo Nordisk pharmaceutical company and Novartis pharmaceutical company.\u202fRoger Mills discloses that he is a board member of Addex and Enterin. Jeffrey Cummings has provided consultation to Acadia, Acumen, ALZpath, Annovis, Artery, Axsome, Biogen, Biohaven, Bristol-Myers Squib, Cervomed, Eisai, Fosun, GAP Foundation, Green Valley, Hummingbird Diagnostics. IGC, Janssen, Julius Clinical, Kinoxis, Lighthouse, Lilly, Lundbeck, LSP\/eqt, Merck, MoCA Cognition, Novo Nordisk, NSC Therapeutics, Optoceutics, Otsuka, Praxis, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, sinaptica, T-Neuro, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies. Dr. Cummings is co-founder of CNS Innovations and Mangrove Therapeutics. Zahinoor Ismail has served as an advisor\/consultant to CADTH, EISAI, Lilly, Lundbeck\/Otsuka, Novo Nordisk, and Roche. Maria Soto declares that she has provided consultation to Acadia, Biogen, MapLight, Bristol-Myers Squib, Lilly, Lundbeck, Otsuka, Roche, Eisai. Jacobo Mintzer declares that his consultancy for ACADIA, the American Association of Retired Persons (AARP)-supported Global Council on Brain Health (GCBH), AiOmed, the Alliance for Aging Research, Axsome Therapeutics Inc., Exciva, EQT Group, Genentech (affiliate of F. Hoffmann-La Roche Ltd), Lundbeck, Otsuka\/Avanir, and Praxis Bioresearch. Dr. Mintzer is a Steering Committee Member for the Alzheimer\u2019s Clinical Trials Consortium (ACTC), and the Alzheimer\u2019s Therapeutic Research Institute (ATRI). He is a Board Member of the Alzheimer\u2019s Association, SC Chapter, and the Technology Accelerator Company (TAC), as well as an Association Member of the International Psychogeriatric Association (IPA). Dr. Mintzer is a stockholder and the VP for Clinical Affairs for NeuroQuest, a majority owner of Biopharma Connex, and a majority partner for Recruitment Partners. He is a member of the Nabilone for Agitation Blinded Intervention Trial (NAB-IT) and the Cannabinoid Liquid Medication Intervention Trial (CALM-IT) Data Safety and Monitoring Boards (DSMB). Finally, he is receiving funding to conduct clinical research trials from the National Institute on Aging (NIA), the National Institutes for Health (NIH), the Alzheimer\u2019s Association, Eisai Inc., the Alzheimer\u2019s Drug Discovery Foundation (ADDF), Cognition Therapeutics, Inc., GHR Foundation, and Suven Life Sciences Ltd., Serge Gauthier is an advisor to SAB for Abbvie, Advantage, Alzheon, AmyriAD, Eisai Canada, Enigma USA, Lilly Canada, Novo Nordisk Canada, TauRx. Carol Routledge discloses she is on the Board of Directors of Alzinova AB. Howard Fillit declares that he is a consultant for Alector. Roger Lane is an employee of, and hold stock\/stock options in, Ionis. Anne Corbett discloses financial relationships with Suven and Janssen pharmaceutical companies for consultancy work. All other authors have no conflicts of interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}